

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kolker, Daniel E.
Sheet	1	of	2	Attorney Docket Number	015270-008920US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	222	WO	08/103472	A2	08-28-2008	Elan Pharmaceuticals, Inc. et al.		<input type="checkbox"/>
	235	WO	03/000714	A2	01-03-2003	New York University		<input type="checkbox"/>
	236	WO	03/000714	A3	01-03-2003	New York University		<input type="checkbox"/>
	227	WO	01/60794	A2	08-23-2001	University of California		<input type="checkbox"/>
	228	WO	01/60794	A3	08-23-2001	University of California		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kolker, Daniel E.
Sheet	2	of	2	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	226	ANDERSON et al., "Phosphorylation of SER-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease," The Journal of Biological Chemistry, 281:29739-29752 (2006).	<input type="checkbox"/>
	224	CHILCOTE et al., "Comparison of alpha-synuclein species in Lewy bodies and the soluble fraction of diffuse Lewy body disease brain," Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, US (2003) Abstract only.	<input type="checkbox"/>
	237	EP 03783083.3 European Supplementary Search Report completed 10/10/2008.	<input type="checkbox"/>
	238	EP 05814041.9 European Supplementary Search Report completed 10/29/2008.	<input type="checkbox"/>
	229	HASHIMOTO et al., "β-synuclein inhibits [alpha]-synuclein aggregation: A possible role as an anti-Parkinsonian factor", NEURON, 32(2):213-223 (2001).	<input type="checkbox"/>
	233	HEISER et al., "Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy," Proceedings of the National Academy of Sciences of USA, 97(12):6739-6744 (2000), Abstract only.	<input type="checkbox"/>
	232	LECERF et al., "Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease," Proceeding of the National Academy of Sciences of USA, 98(8):4764-4769 (2001).	<input type="checkbox"/>
	225	LEE et al., "Truncated alpha-synuclein is generate in vivo and potentiates alpha synuclein aggregation," Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, US (2003), Abstract only.	<input type="checkbox"/>
	234	ROCHET et al., "Inhabitation of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse α-synuclein" Biochemistry, 39(35):10619-10626 (2000), abstract only.	<input type="checkbox"/>
	223	TOFARIS et al., "Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function," The Journal of Biological Chemistry, 278: 44405-44411 (2003).	<input type="checkbox"/>
	231	WANKER, "Protein aggregation in Huntington's and Parkinson's disease: Implications or therapy," Molecular Medicine Today 2000 GB, 6(10):387-397 (2000), Abstract only.	<input type="checkbox"/>
	230	WINDISCH et al., "Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory [beta]-synuclein-derived peptides," Journal of Molecular Neuroscience, 19(2): 63-69 (2002) abstract only.	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.